Andrew Beavis

Andrew Beavis is the Senior Director of Quality Control at Talaris Therapeutics. Andrew has over 30 years of experience in academic, contract research, biotechnology and pharmaceutical organizations. He has directed analytical development at Novartis for cell therapy products including the first FDA-approved CAR-T cell therapy Kymriah® and at Medarex (now part of BMS) for biologic products including Yervoy® and  Opdivo®. He has managed bioanalytical testing operations for Schering-Plough, ICON Central Laboratories and Esoterix Clinical Trials Services. In addition, he has held key research and operational rolesin education institutions such as Princeton, Cornell and Rutgers Universities. Andrew has authored numerous publications in peer-reviewed scientific journals, with particular emphasis on applications of flow cytometry and cell-based analytical methods for drug development, and has presented at multiple international scientific congresses. Andrew holds a B.Sc (Honours) in Applied Biochemistry from Brunel University, London, UK